Education
About Us
Working with TipRanks
Follow Us
Pacific Biosciences (PACB)
NASDAQ:PACB
PACB Stock Chart & Stats
$1.82
$0.14(7.00%)
At close: 4:00 PM EST
$1.82
$0.14(7.00%)
Day’s Range― - ―
52-Week Range$0.85 - $2.73
Previous CloseN/A
Volume8.28M
Average Volume (3M)7.62M
Market Cap
$549.47M
Enterprise Value$786.21M
Total Cash (Recent Filing)$298.65M
Total Debt (Recent Filing)$703.08M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Feb 12, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding301,907,440
10 Day Avg. Volume5,991,912
30 Day Avg. Volume7,620,440
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)0.99
Price to Sales (P/S)3.26
P/FCF Ratio-2.37
Enterprise Value/Market Cap1.43
Enterprise Value/Revenue5.09
Enterprise Value/Gross Profit20.02
Enterprise Value/Ebitda-7.60
Forecast
1Y Price Target
$2.40Price Target Upside31.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.86
Revenue Forecast (FY)$157.27M
Bulls Say, Bears Say
Bulls Say
Financial PerformanceGMs continued to improve to 42% and burn was more moderate.
Market ExpansionPacBio's new multi-use SMRT cells could unlock larger projects for customers and benefit PACB's gross margin.
Product InnovationThe company views the launch of the new SPRQ-Nx chemistry as a major catalyst/inflection point with early access demand very strong.
Bears Say
Market ChallengesThe instrument environment remains challenging, and new Vega placements still came up short.
Revenue GuidanceThe company narrowed its 2025 revenue guidance, lowering the midpoint, due to ongoing NIH budget uncertainty and lower-than-expected placements.
Sales PerformanceSales missed by 4% due to weak instruments while consumables grew 15% and beat by 11%.
Pacific Biosciences News
PACB FAQ
What was Pacific Biosciences’s price range in the past 12 months?
Pacific Biosciences lowest stock price was $0.85 and its highest was $2.73 in the past 12 months.
What is Pacific Biosciences’s market cap?
Pacific Biosciences’s market cap is $549.47M.
When is Pacific Biosciences’s upcoming earnings report date?
Pacific Biosciences’s upcoming earnings report date is Feb 12, 2026 which is in 50 days.
How were Pacific Biosciences’s earnings last quarter?
Pacific Biosciences released its earnings results on Nov 05, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.151 by $0.021.
Is Pacific Biosciences overvalued?
According to Wall Street analysts Pacific Biosciences’s price is currently Undervalued.
Does Pacific Biosciences pay dividends?
Pacific Biosciences does not currently pay dividends.
What is Pacific Biosciences’s EPS estimate?
Pacific Biosciences’s EPS estimate is -0.15.
How many shares outstanding does Pacific Biosciences have?
Pacific Biosciences has 301,907,440 shares outstanding.
What happened to Pacific Biosciences’s price movement after its last earnings report?
Pacific Biosciences reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.151. Following the earnings report the stock price went down -7.292%.
Which hedge fund is a major shareholder of Pacific Biosciences?
Currently, no hedge funds are holding shares in PACB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pacific Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.40 (31.87% Upside)
$2.40 (31.87% Upside)
Blogger Sentiment
Bearish
PACB Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 5.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 9.0%
Last 30 Days ▼ 9.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.61%
12-Months-Change
Fundamentals
Return on Equity
-205.41%
Trailing 12-Months
Asset Growth
-44.61%
Trailing 12-Months
Company Description
Pacific Biosciences
Pacific Biosciences (PACB) is a biotechnology company specializing in the development and manufacture of innovative DNA sequencing technologies. Founded in 2004 and headquartered in Menlo Park, California, the company operates primarily in the genomics sector, providing high-quality, long-read sequencing solutions that empower researchers in various fields such as genomics, transcriptomics, and epigenomics. Its core products include the Sequel II and Sequel IIe systems, which are designed to deliver comprehensive and accurate genomic data for applications ranging from basic research to clinical diagnostics.
PACB Company Deck
PACB Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive and negative aspects. While there were significant achievements in consumable revenue, gross margin improvements, and clinical advancements, these were tempered by an overall decline in total revenue and challenges in the funding environment impacting instrument sales.View all PACB earnings summariesPACB Stock 12 Month Forecast
Average Price Target
$2.40
▲(31.87% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---